Stiripentol for the Treatment of Refractory Status Epilepticus
- Registration Number
- NCT06540378
- Lead Sponsor
- University Hospital Marburg
- Brief Summary
The investigators retrospectively analyzed all patients who were admitted to the Department of Neurology at Marburg University Hospital between 2013 and 2023 with a diagnosis of (super)-refractory status epilepticus and who received additional treatment of SE with STP. All patients who received STP during the SE were included, regardless of previous medication.
- Detailed Description
The investigators retrospectively analyzed all patients who were admitted to the Department of Neurology, University Hospital Marburg, Germany, between 2013 and 2023 with a diagnosis of status epilepticus, who received additional treatment of SE with STP. They were able to identify 25 patients who received STP as add on therapy. All these patients suffered from RSE or SRSE. Since there was no SOP or treatment algorithm available, they have listed the individual treatment regimens in Table 2. 5 of these patients were previously published in a case series (Strzelczyk et al. 2015).
Treatment success was defined as continuous interruption of the SE. Descriptive statistics are reported as absolute numbers and percentages, mean ± standard deviation (SD) or median ± median absolute deviation.
The study was approved by the local IRB.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
- adult patients who suffered from RSE or SRSE and received STP as add on therapy.
- children
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description STP in RSE or SRSE Stiripentol Patients received additional treatment of SE with STP
- Primary Outcome Measures
Name Time Method Number of participants with cessation of SE by STP up to one week Median dose of STP From date of first admission until the date of first documented improvement of status epilepticus or severe sideeffects or termination due to lack of effect or date of death from any cause, whichever came first, assessed up to 12 months Cessation of Status epilepticus time to cessation of SE, normally during the first days of admission, up to one week
- Secondary Outcome Measures
Name Time Method Individualised order of the anti-seizure medication administered From date of first admission until the date of first documented improvement of status epilepticus or severe sideeffects or termination due to lack of effect or date of death from any cause, whichever came first, assessed up to 12 months Treatment in combination with other anti-seizure medication From date of first admission until the date of first documented improvement of status epilepticus or severe sideeffects or termination due to lack of effect or date of death from any cause, whichever came first, assessed up to 12 months